SAN

82.47

+0.33%↑

MRK1

119.85

+0.76%↑

SHL.DE

44.33

-0.87%↓

ARGX

734

+1.1%↑

FRE

48.33

+0.86%↑

SAN

82.47

+0.33%↑

MRK1

119.85

+0.76%↑

SHL.DE

44.33

-0.87%↓

ARGX

734

+1.1%↑

FRE

48.33

+0.86%↑

SAN

82.47

+0.33%↑

MRK1

119.85

+0.76%↑

SHL.DE

44.33

-0.87%↓

ARGX

734

+1.1%↑

FRE

48.33

+0.86%↑

SAN

82.47

+0.33%↑

MRK1

119.85

+0.76%↑

SHL.DE

44.33

-0.87%↓

ARGX

734

+1.1%↑

FRE

48.33

+0.86%↑

SAN

82.47

+0.33%↑

MRK1

119.85

+0.76%↑

SHL.DE

44.33

-0.87%↓

ARGX

734

+1.1%↑

FRE

48.33

+0.86%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

18.5 0.54

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.2

Max

18.92

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+22.99% upside

Turustatistika
By TradingEconomics
Turukapital	25M 932M
Eelmine avamishind	17.96
Eelmine sulgemishind	18.5

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 17:29 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. dets 2025, 16:47 UTC

Suurimad hinnamuutused turgudel

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. dets 2025, 16:10 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19. dets 2025, 22:33 UTC

Tulu

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. dets 2025, 22:19 UTC

Tulu

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. dets 2025, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 21:44 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 21:38 UTC

Tulu

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. dets 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. dets 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. dets 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. dets 2025, 18:00 UTC

Market Talk

Tulu

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. dets 2025, 17:41 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 17:24 UTC

Market Talk

Tulu

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. dets 2025, 16:29 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. dets 2025, 16:20 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. dets 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. dets 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. dets 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. dets 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 16:04 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. dets 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. dets 2025, 15:09 UTC

Tulu

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

22.99% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 22.99%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.